HLA B Leader in Patients With Psoriatic Arthritis

Recruiting N/A Interventional Study
Psoriatic Arthritis HLA b Leader HLA B27
Ready to participate?

Review the details below, then apply to join this clinical trial.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule. Given thi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * For the "Patient" group: * Patient over 18 years of age * Patient affiliated to a social security scheme * Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie. * For the "control" group: * Individuals over 18 years …
Contacts

Vincent Goeb, Pr

33+3.22.08.83.71

Goeb.vincent@chu-amiens.fr

CONTACT